Research and analysis, minus the hype, the filler, and the three paragraphs before the recipe.
We produce original research, market analysis, and practical guides across business, technology, and public policy. Most sites in our position would sell you a newsletter here. We would rather just hand you the work: clear, sourced, written by people who read the footnotes on purpose.
Recent work
Does Insurance Cover GLP-1 Drugs Like Ozempic and Wegovy in 2026?
Medicare opens a temporary GLP-1 program in July 2026, and Medicaid is shifting too. Here is who qualifies, what it costs, and how to confirm your own coverage before you count on it.
Read the piece →How Tariffs Actually Work, and How They Reach the Prices You Pay
Tariffs are paid at the border, but the cost travels. Here is how a tariff actually works, how to trace it to a price tag, and what the 2026 estimates really say.
Read the piece →The Average Car Insurance Cost in 2026, and Why Yours May Differ
The average full-coverage premium is around 2,500 dollars a year, but averages hide a lot. Here is what is driving the price and how to read a 2026 quote without taking it on faith.
Read the piece →We are an independent research and editorial group. We publish original analysis, practical guides, and market intelligence, and we license that work to other sites. Not every site that asks. Only the ones that meet our standards.
We do not publish sponsored content, native advertising, or anything written for the sole purpose of building links. Every piece carries a real byline, cites verified sources, and traces back to an editor who will answer for it. That used to be the baseline. Now it counts as a position.
More about who we are →Got a question about our research?
Editorial inquiries, correction requests, licensing questions. We read all of them, and we reply to most within two business days.
Get in touch →